nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A7—Paclitaxel—ovarian cancer	0.0791	0.145	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0791	0.145	CbGbCtD
Aprepitant—CYP3A5—Paclitaxel—ovarian cancer	0.0593	0.109	CbGbCtD
Aprepitant—CYP3A7—Docetaxel—ovarian cancer	0.0572	0.105	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0572	0.105	CbGbCtD
Aprepitant—CYP3A4—Topotecan—ovarian cancer	0.0467	0.0855	CbGbCtD
Aprepitant—CYP3A5—Docetaxel—ovarian cancer	0.0429	0.0785	CbGbCtD
Aprepitant—CYP2C9—Paclitaxel—ovarian cancer	0.0398	0.0728	CbGbCtD
Aprepitant—CYP3A4—Vinorelbine—ovarian cancer	0.0329	0.0603	CbGbCtD
Aprepitant—CYP3A4—Paclitaxel—ovarian cancer	0.0231	0.0423	CbGbCtD
Aprepitant—CYP3A4—Docetaxel—ovarian cancer	0.0167	0.0306	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—ovarian cancer	0.0125	0.0228	CbGbCtD
Aprepitant—Pneumonia—Epirubicin—ovarian cancer	0.000222	0.00051	CcSEcCtD
Aprepitant—Convulsion—Docetaxel—ovarian cancer	0.000222	0.000509	CcSEcCtD
Aprepitant—Paraesthesia—Paclitaxel—ovarian cancer	0.000222	0.000508	CcSEcCtD
Aprepitant—Hypertension—Docetaxel—ovarian cancer	0.000221	0.000507	CcSEcCtD
Aprepitant—Infestation NOS—Epirubicin—ovarian cancer	0.000221	0.000507	CcSEcCtD
Aprepitant—Infestation—Epirubicin—ovarian cancer	0.000221	0.000507	CcSEcCtD
Aprepitant—Dyspnoea—Paclitaxel—ovarian cancer	0.00022	0.000504	CcSEcCtD
Aprepitant—Somnolence—Paclitaxel—ovarian cancer	0.000219	0.000503	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000219	0.000503	CcSEcCtD
Aprepitant—Chest pain—Docetaxel—ovarian cancer	0.000218	0.0005	CcSEcCtD
Aprepitant—Arthralgia—Docetaxel—ovarian cancer	0.000218	0.0005	CcSEcCtD
Aprepitant—Myalgia—Docetaxel—ovarian cancer	0.000218	0.0005	CcSEcCtD
Aprepitant—Nausea—Vinorelbine—ovarian cancer	0.000218	0.000499	CcSEcCtD
Aprepitant—Renal failure—Epirubicin—ovarian cancer	0.000217	0.000498	CcSEcCtD
Aprepitant—Dyspepsia—Paclitaxel—ovarian cancer	0.000217	0.000498	CcSEcCtD
Aprepitant—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000217	0.000497	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000217	0.000497	CcSEcCtD
Aprepitant—Stomatitis—Epirubicin—ovarian cancer	0.000216	0.000494	CcSEcCtD
Aprepitant—Urinary tract infection—Epirubicin—ovarian cancer	0.000215	0.000493	CcSEcCtD
Aprepitant—Conjunctivitis—Epirubicin—ovarian cancer	0.000215	0.000493	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—ovarian cancer	0.000215	0.000492	CcSEcCtD
Aprepitant—Dysuria—Doxorubicin—ovarian cancer	0.000215	0.000492	CcSEcCtD
Aprepitant—Decreased appetite—Paclitaxel—ovarian cancer	0.000215	0.000492	CcSEcCtD
Aprepitant—Dry mouth—Docetaxel—ovarian cancer	0.000213	0.000489	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000213	0.000489	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000213	0.000488	CcSEcCtD
Aprepitant—Fatigue—Paclitaxel—ovarian cancer	0.000213	0.000488	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—ovarian cancer	0.000212	0.000486	CcSEcCtD
Aprepitant—Constipation—Paclitaxel—ovarian cancer	0.000211	0.000484	CcSEcCtD
Aprepitant—Pain—Paclitaxel—ovarian cancer	0.000211	0.000484	CcSEcCtD
Aprepitant—Haematuria—Epirubicin—ovarian cancer	0.000211	0.000483	CcSEcCtD
Aprepitant—Confusional state—Docetaxel—ovarian cancer	0.000211	0.000483	CcSEcCtD
Aprepitant—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00021	0.00048	CcSEcCtD
Aprepitant—Anaphylactic shock—Docetaxel—ovarian cancer	0.000209	0.000479	CcSEcCtD
Aprepitant—Oedema—Docetaxel—ovarian cancer	0.000209	0.000479	CcSEcCtD
Aprepitant—Weight increased—Doxorubicin—ovarian cancer	0.000209	0.000479	CcSEcCtD
Aprepitant—Infection—Docetaxel—ovarian cancer	0.000208	0.000476	CcSEcCtD
Aprepitant—Weight decreased—Doxorubicin—ovarian cancer	0.000208	0.000476	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000207	0.000475	CcSEcCtD
Aprepitant—Pneumonia—Doxorubicin—ovarian cancer	0.000206	0.000472	CcSEcCtD
Aprepitant—Shock—Docetaxel—ovarian cancer	0.000206	0.000472	CcSEcCtD
Aprepitant—Nervous system disorder—Docetaxel—ovarian cancer	0.000205	0.00047	CcSEcCtD
Aprepitant—Thrombocytopenia—Docetaxel—ovarian cancer	0.000205	0.000469	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—ovarian cancer	0.000205	0.000469	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—ovarian cancer	0.000205	0.000469	CcSEcCtD
Aprepitant—Tachycardia—Docetaxel—ovarian cancer	0.000204	0.000468	CcSEcCtD
Aprepitant—Feeling abnormal—Paclitaxel—ovarian cancer	0.000203	0.000466	CcSEcCtD
Aprepitant—Skin disorder—Docetaxel—ovarian cancer	0.000203	0.000466	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000203	0.000465	CcSEcCtD
Aprepitant—Bradycardia—Epirubicin—ovarian cancer	0.000202	0.000463	CcSEcCtD
Aprepitant—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000202	0.000462	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—ovarian cancer	0.000201	0.000461	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000201	0.00046	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—ovarian cancer	0.0002	0.000457	CcSEcCtD
Aprepitant—Anorexia—Docetaxel—ovarian cancer	0.000199	0.000457	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—ovarian cancer	0.000199	0.000456	CcSEcCtD
Aprepitant—Urinary tract infection—Doxorubicin—ovarian cancer	0.000199	0.000456	CcSEcCtD
Aprepitant—Hypoaesthesia—Epirubicin—ovarian cancer	0.000198	0.000453	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—ovarian cancer	0.000197	0.000452	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—ovarian cancer	0.000196	0.000449	CcSEcCtD
Aprepitant—Urticaria—Paclitaxel—ovarian cancer	0.000196	0.000449	CcSEcCtD
Aprepitant—Hypotension—Docetaxel—ovarian cancer	0.000195	0.000448	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—ovarian cancer	0.000195	0.000447	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—ovarian cancer	0.000195	0.000447	CcSEcCtD
Aprepitant—Body temperature increased—Paclitaxel—ovarian cancer	0.000195	0.000447	CcSEcCtD
Aprepitant—Abdominal pain—Paclitaxel—ovarian cancer	0.000195	0.000447	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—ovarian cancer	0.000195	0.000446	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000191	0.000437	CcSEcCtD
Aprepitant—Insomnia—Docetaxel—ovarian cancer	0.000189	0.000434	CcSEcCtD
Aprepitant—Paraesthesia—Docetaxel—ovarian cancer	0.000188	0.00043	CcSEcCtD
Aprepitant—Erythema multiforme—Epirubicin—ovarian cancer	0.000188	0.00043	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—ovarian cancer	0.000187	0.000429	CcSEcCtD
Aprepitant—Dyspnoea—Docetaxel—ovarian cancer	0.000186	0.000427	CcSEcCtD
Aprepitant—Somnolence—Docetaxel—ovarian cancer	0.000186	0.000426	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—ovarian cancer	0.000186	0.000425	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—ovarian cancer	0.000185	0.000424	CcSEcCtD
Aprepitant—Flushing—Epirubicin—ovarian cancer	0.000184	0.000422	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—ovarian cancer	0.000184	0.000422	CcSEcCtD
Aprepitant—Dyspepsia—Docetaxel—ovarian cancer	0.000184	0.000422	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000183	0.000419	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—ovarian cancer	0.000182	0.000418	CcSEcCtD
Aprepitant—Decreased appetite—Docetaxel—ovarian cancer	0.000182	0.000417	CcSEcCtD
Aprepitant—Hypersensitivity—Paclitaxel—ovarian cancer	0.000182	0.000417	CcSEcCtD
Aprepitant—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000181	0.000416	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000181	0.000414	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000181	0.000414	CcSEcCtD
Aprepitant—Fatigue—Docetaxel—ovarian cancer	0.00018	0.000413	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—ovarian cancer	0.00018	0.000413	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—ovarian cancer	0.00018	0.000413	CcSEcCtD
Aprepitant—Immune system disorder—Epirubicin—ovarian cancer	0.000179	0.000411	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—ovarian cancer	0.000179	0.00041	CcSEcCtD
Aprepitant—Constipation—Docetaxel—ovarian cancer	0.000179	0.00041	CcSEcCtD
Aprepitant—Pain—Docetaxel—ovarian cancer	0.000179	0.00041	CcSEcCtD
Aprepitant—Chills—Epirubicin—ovarian cancer	0.000178	0.000408	CcSEcCtD
Aprepitant—Asthenia—Paclitaxel—ovarian cancer	0.000177	0.000406	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—ovarian cancer	0.000175	0.000402	CcSEcCtD
Aprepitant—Pruritus—Paclitaxel—ovarian cancer	0.000175	0.0004	CcSEcCtD
Aprepitant—Mental disorder—Epirubicin—ovarian cancer	0.000174	0.000399	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—ovarian cancer	0.000174	0.000398	CcSEcCtD
Aprepitant—Erythema—Epirubicin—ovarian cancer	0.000173	0.000396	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—ovarian cancer	0.000173	0.000396	CcSEcCtD
Aprepitant—Feeling abnormal—Docetaxel—ovarian cancer	0.000172	0.000395	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—ovarian cancer	0.000172	0.000394	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—ovarian cancer	0.000171	0.000393	CcSEcCtD
Aprepitant—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000171	0.000392	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—ovarian cancer	0.000171	0.000391	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—ovarian cancer	0.000171	0.000391	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—ovarian cancer	0.00017	0.00039	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—ovarian cancer	0.000169	0.000388	CcSEcCtD
Aprepitant—Diarrhoea—Paclitaxel—ovarian cancer	0.000169	0.000387	CcSEcCtD
Aprepitant—Back pain—Epirubicin—ovarian cancer	0.000167	0.000383	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—ovarian cancer	0.000167	0.000382	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—ovarian cancer	0.000166	0.000381	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—ovarian cancer	0.000166	0.00038	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000166	0.00038	CcSEcCtD
Aprepitant—Abdominal pain—Docetaxel—ovarian cancer	0.000165	0.000379	CcSEcCtD
Aprepitant—Body temperature increased—Docetaxel—ovarian cancer	0.000165	0.000379	CcSEcCtD
Aprepitant—Chills—Doxorubicin—ovarian cancer	0.000165	0.000378	CcSEcCtD
Aprepitant—Dizziness—Paclitaxel—ovarian cancer	0.000163	0.000374	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—ovarian cancer	0.000162	0.000372	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—ovarian cancer	0.000161	0.000369	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—ovarian cancer	0.00016	0.000368	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—ovarian cancer	0.00016	0.000367	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—ovarian cancer	0.00016	0.000367	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—ovarian cancer	0.00016	0.000366	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—ovarian cancer	0.000158	0.000361	CcSEcCtD
Aprepitant—Vomiting—Paclitaxel—ovarian cancer	0.000157	0.00036	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—ovarian cancer	0.000157	0.000359	CcSEcCtD
Aprepitant—Malaise—Epirubicin—ovarian cancer	0.000156	0.000357	CcSEcCtD
Aprepitant—Rash—Paclitaxel—ovarian cancer	0.000156	0.000357	CcSEcCtD
Aprepitant—Dermatitis—Paclitaxel—ovarian cancer	0.000155	0.000356	CcSEcCtD
Aprepitant—Syncope—Epirubicin—ovarian cancer	0.000155	0.000355	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—ovarian cancer	0.000155	0.000355	CcSEcCtD
Aprepitant—Headache—Paclitaxel—ovarian cancer	0.000155	0.000354	CcSEcCtD
Aprepitant—Hypersensitivity—Docetaxel—ovarian cancer	0.000154	0.000353	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—ovarian cancer	0.000154	0.000352	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—ovarian cancer	0.000153	0.00035	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—ovarian cancer	0.000152	0.000348	CcSEcCtD
Aprepitant—Cough—Epirubicin—ovarian cancer	0.000151	0.000346	CcSEcCtD
Aprepitant—Asthenia—Docetaxel—ovarian cancer	0.00015	0.000344	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—ovarian cancer	0.00015	0.000343	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—ovarian cancer	0.000149	0.000342	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000148	0.00034	CcSEcCtD
Aprepitant—Pruritus—Docetaxel—ovarian cancer	0.000148	0.000339	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—ovarian cancer	0.000148	0.000339	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—ovarian cancer	0.000147	0.000337	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—ovarian cancer	0.000147	0.000337	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—ovarian cancer	0.000147	0.000337	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—ovarian cancer	0.000147	0.000336	CcSEcCtD
Aprepitant—Nausea—Paclitaxel—ovarian cancer	0.000147	0.000336	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000146	0.000335	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—ovarian cancer	0.000145	0.000333	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—ovarian cancer	0.000144	0.000331	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—ovarian cancer	0.000144	0.00033	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—ovarian cancer	0.000143	0.000329	CcSEcCtD
Aprepitant—Diarrhoea—Docetaxel—ovarian cancer	0.000143	0.000328	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—ovarian cancer	0.000142	0.000326	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—ovarian cancer	0.000141	0.000324	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—ovarian cancer	0.000141	0.000323	CcSEcCtD
Aprepitant—Oedema—Epirubicin—ovarian cancer	0.000141	0.000323	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—ovarian cancer	0.000141	0.000322	CcSEcCtD
Aprepitant—Infection—Epirubicin—ovarian cancer	0.00014	0.000321	CcSEcCtD
Aprepitant—Cough—Doxorubicin—ovarian cancer	0.00014	0.00032	CcSEcCtD
Aprepitant—Shock—Epirubicin—ovarian cancer	0.000139	0.000318	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—ovarian cancer	0.000139	0.000318	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—ovarian cancer	0.000138	0.000317	CcSEcCtD
Aprepitant—Dizziness—Docetaxel—ovarian cancer	0.000138	0.000317	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—ovarian cancer	0.000138	0.000317	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—ovarian cancer	0.000138	0.000316	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—ovarian cancer	0.000138	0.000316	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—ovarian cancer	0.000137	0.000314	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—ovarian cancer	0.000136	0.000313	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—ovarian cancer	0.000136	0.000312	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—ovarian cancer	0.000136	0.000312	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—ovarian cancer	0.000136	0.000312	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—ovarian cancer	0.000136	0.000311	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000135	0.00031	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—ovarian cancer	0.000135	0.000308	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—ovarian cancer	0.000134	0.000308	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—ovarian cancer	0.000133	0.000305	CcSEcCtD
Aprepitant—Vomiting—Docetaxel—ovarian cancer	0.000133	0.000305	CcSEcCtD
Aprepitant—Rash—Docetaxel—ovarian cancer	0.000132	0.000302	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—ovarian cancer	0.000132	0.000302	CcSEcCtD
Aprepitant—Dermatitis—Docetaxel—ovarian cancer	0.000132	0.000302	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—ovarian cancer	0.000132	0.000302	CcSEcCtD
Aprepitant—Headache—Docetaxel—ovarian cancer	0.000131	0.0003	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—ovarian cancer	0.000131	0.000299	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000131	0.000299	CcSEcCtD
Aprepitant—Infection—Doxorubicin—ovarian cancer	0.00013	0.000297	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000129	0.000295	CcSEcCtD
Aprepitant—Shock—Doxorubicin—ovarian cancer	0.000128	0.000294	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—ovarian cancer	0.000128	0.000293	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000128	0.000293	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—ovarian cancer	0.000128	0.000292	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—ovarian cancer	0.000127	0.000292	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—ovarian cancer	0.000127	0.000291	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—ovarian cancer	0.000127	0.00029	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000126	0.000289	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—ovarian cancer	0.000126	0.000288	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—ovarian cancer	0.000125	0.000287	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—ovarian cancer	0.000124	0.000285	CcSEcCtD
Aprepitant—Nausea—Docetaxel—ovarian cancer	0.000124	0.000285	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—ovarian cancer	0.000124	0.000285	CcSEcCtD
Aprepitant—Decreased appetite—Epirubicin—ovarian cancer	0.000123	0.000281	CcSEcCtD
Aprepitant—Hypotension—Doxorubicin—ovarian cancer	0.000122	0.00028	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000122	0.000279	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—ovarian cancer	0.000122	0.000279	CcSEcCtD
Aprepitant—Pain—Epirubicin—ovarian cancer	0.000121	0.000276	CcSEcCtD
Aprepitant—Constipation—Epirubicin—ovarian cancer	0.000121	0.000276	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000119	0.000273	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—ovarian cancer	0.000118	0.000271	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—ovarian cancer	0.000117	0.000269	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—ovarian cancer	0.000116	0.000267	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—ovarian cancer	0.000116	0.000266	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—ovarian cancer	0.000116	0.000266	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000115	0.000264	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—ovarian cancer	0.000115	0.000263	CcSEcCtD
Aprepitant—Decreased appetite—Doxorubicin—ovarian cancer	0.000113	0.00026	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000113	0.000258	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—ovarian cancer	0.000113	0.000258	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—ovarian cancer	0.000112	0.000257	CcSEcCtD
Aprepitant—Pain—Doxorubicin—ovarian cancer	0.000112	0.000256	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—ovarian cancer	0.000112	0.000256	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—ovarian cancer	0.000112	0.000256	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—ovarian cancer	0.000112	0.000256	CcSEcCtD
Aprepitant—Feeling abnormal—Doxorubicin—ovarian cancer	0.000108	0.000247	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000107	0.000245	CcSEcCtD
Aprepitant—Hypersensitivity—Epirubicin—ovarian cancer	0.000104	0.000238	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—ovarian cancer	0.000104	0.000238	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—ovarian cancer	0.000103	0.000236	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—ovarian cancer	0.000103	0.000236	CcSEcCtD
Aprepitant—Asthenia—Epirubicin—ovarian cancer	0.000101	0.000232	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—ovarian cancer	9.98e-05	0.000229	CcSEcCtD
Aprepitant—Diarrhoea—Epirubicin—ovarian cancer	9.65e-05	0.000221	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—ovarian cancer	9.62e-05	0.00022	CcSEcCtD
Aprepitant—Asthenia—Doxorubicin—ovarian cancer	9.37e-05	0.000215	CcSEcCtD
Aprepitant—Dizziness—Epirubicin—ovarian cancer	9.33e-05	0.000214	CcSEcCtD
Aprepitant—Pruritus—Doxorubicin—ovarian cancer	9.24e-05	0.000212	CcSEcCtD
Aprepitant—Vomiting—Epirubicin—ovarian cancer	8.97e-05	0.000206	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—ovarian cancer	8.93e-05	0.000205	CcSEcCtD
Aprepitant—Rash—Epirubicin—ovarian cancer	8.9e-05	0.000204	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—ovarian cancer	8.89e-05	0.000204	CcSEcCtD
Aprepitant—Headache—Epirubicin—ovarian cancer	8.84e-05	0.000203	CcSEcCtD
Aprepitant—Dizziness—Doxorubicin—ovarian cancer	8.63e-05	0.000198	CcSEcCtD
Aprepitant—Nausea—Epirubicin—ovarian cancer	8.38e-05	0.000192	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—ovarian cancer	8.3e-05	0.00019	CcSEcCtD
Aprepitant—Rash—Doxorubicin—ovarian cancer	8.23e-05	0.000189	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—ovarian cancer	8.22e-05	0.000188	CcSEcCtD
Aprepitant—Headache—Doxorubicin—ovarian cancer	8.18e-05	0.000187	CcSEcCtD
Aprepitant—Nausea—Doxorubicin—ovarian cancer	7.75e-05	0.000178	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—EREG—ovarian cancer	3.04e-05	0.00176	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—APC—ovarian cancer	2.95e-05	0.0017	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CG—ovarian cancer	2.95e-05	0.0017	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—NRAS—ovarian cancer	2.95e-05	0.0017	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PGR—ovarian cancer	2.85e-05	0.00165	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—MAPK3—ovarian cancer	2.82e-05	0.00163	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	2.7e-05	0.00156	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—MAPK1—ovarian cancer	2.69e-05	0.00155	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—EGFR—ovarian cancer	2.68e-05	0.00155	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CG—ovarian cancer	2.68e-05	0.00155	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NME2—ovarian cancer	2.68e-05	0.00155	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	2.67e-05	0.00154	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PARP1—ovarian cancer	2.65e-05	0.00153	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	2.65e-05	0.00153	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.62e-05	0.00152	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	2.61e-05	0.00151	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CD—ovarian cancer	2.59e-05	0.0015	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—PIK3CA—ovarian cancer	2.57e-05	0.00148	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—KRAS—ovarian cancer	2.54e-05	0.00147	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6ST—ovarian cancer	2.54e-05	0.00147	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	2.49e-05	0.00144	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CG—ovarian cancer	2.44e-05	0.00141	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	2.43e-05	0.00141	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	2.43e-05	0.00141	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	2.43e-05	0.00141	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.39e-05	0.00138	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYTB—ovarian cancer	2.39e-05	0.00138	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CD—ovarian cancer	2.36e-05	0.00136	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PIK3CA—ovarian cancer	2.33e-05	0.00135	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	2.3e-05	0.00133	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ERBB2—ovarian cancer	2.29e-05	0.00132	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MTOR—ovarian cancer	2.26e-05	0.00131	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CB—ovarian cancer	2.26e-05	0.00131	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL8—ovarian cancer	2.17e-05	0.00125	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—ovarian cancer	2.16e-05	0.00125	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PPP2R1A—ovarian cancer	2.15e-05	0.00124	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CD—ovarian cancer	2.14e-05	0.00124	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN1B—ovarian cancer	2.12e-05	0.00122	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AKT1—ovarian cancer	2.1e-05	0.00121	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—BRIP1—ovarian cancer	2.09e-05	0.00121	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPP1CC—ovarian cancer	2.09e-05	0.00121	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CASP3—ovarian cancer	2.08e-05	0.0012	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NME2—ovarian cancer	2.07e-05	0.0012	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2—ovarian cancer	2.07e-05	0.0012	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—ovarian cancer	2.06e-05	0.00119	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CB—ovarian cancer	2.06e-05	0.00119	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.05e-05	0.00118	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.04e-05	0.00118	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCND1—ovarian cancer	2.02e-05	0.00117	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.02e-05	0.00117	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CTNNB1—ovarian cancer	2e-05	0.00116	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—ovarian cancer	1.98e-05	0.00114	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—ovarian cancer	1.96e-05	0.00113	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	1.95e-05	0.00113	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTEN—ovarian cancer	1.95e-05	0.00113	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AKT1—ovarian cancer	1.9e-05	0.0011	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NME2—ovarian cancer	1.89e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2—ovarian cancer	1.89e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CB—ovarian cancer	1.87e-05	0.00108	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—ovarian cancer	1.79e-05	0.00104	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—VEGFA—ovarian cancer	1.76e-05	0.00102	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.76e-05	0.00102	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—STAT3—ovarian cancer	1.75e-05	0.00101	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRAS—ovarian cancer	1.74e-05	0.00101	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYTB—ovarian cancer	1.73e-05	0.000999	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2—ovarian cancer	1.71e-05	0.000991	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TERT—ovarian cancer	1.71e-05	0.000987	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MAPK3—ovarian cancer	1.67e-05	0.000964	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MYC—ovarian cancer	1.62e-05	0.000937	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NME2—ovarian cancer	1.62e-05	0.000934	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.6e-05	0.000927	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MAPK1—ovarian cancer	1.59e-05	0.000917	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—ovarian cancer	1.59e-05	0.000917	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CAV1—ovarian cancer	1.58e-05	0.000913	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ESR1—ovarian cancer	1.52e-05	0.00088	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—BRIP1—ovarian cancer	1.51e-05	0.000873	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPP1CC—ovarian cancer	1.51e-05	0.000873	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KRAS—ovarian cancer	1.5e-05	0.000866	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6ST—ovarian cancer	1.5e-05	0.000866	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—APC—ovarian cancer	1.44e-05	0.000832	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CG—ovarian cancer	1.44e-05	0.000832	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NRAS—ovarian cancer	1.44e-05	0.000832	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.43e-05	0.000829	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—YAP1—ovarian cancer	1.4e-05	0.00081	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—MAPK3—ovarian cancer	1.38e-05	0.000797	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CA—ovarian cancer	1.38e-05	0.000796	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.37e-05	0.000792	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYTB—ovarian cancer	1.34e-05	0.000772	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—ovarian cancer	1.33e-05	0.00077	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—MAPK1—ovarian cancer	1.31e-05	0.000758	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—ovarian cancer	1.31e-05	0.000758	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.31e-05	0.000756	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.31e-05	0.000755	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—ovarian cancer	1.27e-05	0.000736	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CD—ovarian cancer	1.27e-05	0.000731	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.25e-05	0.000724	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NME2—ovarian cancer	1.25e-05	0.000721	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—KRAS—ovarian cancer	1.24e-05	0.000716	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—ovarian cancer	1.22e-05	0.000704	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYTB—ovarian cancer	1.22e-05	0.000704	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.19e-05	0.000688	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—BRIP1—ovarian cancer	1.17e-05	0.000675	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPP1CC—ovarian cancer	1.17e-05	0.000675	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—FASN—ovarian cancer	1.14e-05	0.00066	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CA—ovarian cancer	1.14e-05	0.000658	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AKT1—ovarian cancer	1.12e-05	0.00065	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SLC5A5—ovarian cancer	1.12e-05	0.00065	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ERBB2—ovarian cancer	1.12e-05	0.000646	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.12e-05	0.000646	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MTOR—ovarian cancer	1.1e-05	0.000637	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CB—ovarian cancer	1.1e-05	0.000637	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SLC2A1—ovarian cancer	1.09e-05	0.000627	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.07e-05	0.000616	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.07e-05	0.000616	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—ovarian cancer	1.06e-05	0.000612	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—ovarian cancer	1.05e-05	0.000608	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYTB—ovarian cancer	1.04e-05	0.000602	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP1B1—ovarian cancer	1.04e-05	0.000602	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN1B—ovarian cancer	1.03e-05	0.000598	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AKT1—ovarian cancer	1.02e-05	0.000592	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.02e-05	0.000588	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CASP3—ovarian cancer	1.01e-05	0.000586	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—YAP1—ovarian cancer	1.01e-05	0.000586	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2—ovarian cancer	1.01e-05	0.000585	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—ovarian cancer	1.01e-05	0.000582	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCND1—ovarian cancer	9.87e-06	0.000571	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CTNNB1—ovarian cancer	9.78e-06	0.000565	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—ovarian cancer	9.58e-06	0.000554	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTEN—ovarian cancer	9.53e-06	0.000551	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AKT1—ovarian cancer	9.3e-06	0.000537	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	9.23e-06	0.000534	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPP1CC—ovarian cancer	9.1e-06	0.000526	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—BRIP1—ovarian cancer	9.1e-06	0.000526	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—ovarian cancer	8.61e-06	0.000497	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ABCB1—ovarian cancer	8.57e-06	0.000495	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—ovarian cancer	8.52e-06	0.000493	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.51e-06	0.000492	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—ovarian cancer	8.5e-06	0.000491	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMS—ovarian cancer	8.42e-06	0.000487	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—FASN—ovarian cancer	8.26e-06	0.000477	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MAPK3—ovarian cancer	8.14e-06	0.000471	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC5A5—ovarian cancer	8.13e-06	0.00047	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYTB—ovarian cancer	8.04e-06	0.000464	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—ovarian cancer	7.92e-06	0.000458	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC2A1—ovarian cancer	7.85e-06	0.000454	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—YAP1—ovarian cancer	7.83e-06	0.000453	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.76e-06	0.000449	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.75e-06	0.000448	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MAPK1—ovarian cancer	7.75e-06	0.000448	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—ovarian cancer	7.75e-06	0.000448	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP1B1—ovarian cancer	7.52e-06	0.000435	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—ovarian cancer	7.32e-06	0.000423	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—YAP1—ovarian cancer	7.14e-06	0.000413	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.07e-06	0.000409	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—BRIP1—ovarian cancer	7.02e-06	0.000406	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPP1CC—ovarian cancer	7.02e-06	0.000406	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.82e-06	0.000394	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CAV1—ovarian cancer	6.78e-06	0.000392	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CA—ovarian cancer	6.72e-06	0.000389	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	6.67e-06	0.000386	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.63e-06	0.000383	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—ovarian cancer	6.5e-06	0.000376	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—FASN—ovarian cancer	6.39e-06	0.000369	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC5A5—ovarian cancer	6.28e-06	0.000363	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—ovarian cancer	6.22e-06	0.000359	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.21e-06	0.000359	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ABCB1—ovarian cancer	6.2e-06	0.000358	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CG—ovarian cancer	6.18e-06	0.000357	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—YAP1—ovarian cancer	6.1e-06	0.000353	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMS—ovarian cancer	6.09e-06	0.000352	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC2A1—ovarian cancer	6.07e-06	0.000351	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.04e-06	0.000349	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—ovarian cancer	5.95e-06	0.000344	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.94e-06	0.000343	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—FASN—ovarian cancer	5.82e-06	0.000337	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP1B1—ovarian cancer	5.82e-06	0.000336	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC5A5—ovarian cancer	5.73e-06	0.000331	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC2A1—ovarian cancer	5.53e-06	0.00032	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—ovarian cancer	5.49e-06	0.000317	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CD—ovarian cancer	5.43e-06	0.000314	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.42e-06	0.000313	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.31e-06	0.000307	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP1B1—ovarian cancer	5.3e-06	0.000307	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	5.16e-06	0.000298	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.13e-06	0.000297	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—FASN—ovarian cancer	4.98e-06	0.000288	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CAV1—ovarian cancer	4.9e-06	0.000283	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC5A5—ovarian cancer	4.89e-06	0.000283	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCB1—ovarian cancer	4.79e-06	0.000277	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CB—ovarian cancer	4.73e-06	0.000274	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.73e-06	0.000273	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—YAP1—ovarian cancer	4.71e-06	0.000272	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMS—ovarian cancer	4.7e-06	0.000272	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	4.7e-06	0.000272	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.68e-06	0.000271	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.63e-06	0.000268	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP1B1—ovarian cancer	4.53e-06	0.000262	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CG—ovarian cancer	4.47e-06	0.000258	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCB1—ovarian cancer	4.37e-06	0.000252	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMS—ovarian cancer	4.29e-06	0.000248	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—ovarian cancer	4.09e-06	0.000236	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	4.02e-06	0.000232	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4e-06	0.000231	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CD—ovarian cancer	3.93e-06	0.000227	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—FASN—ovarian cancer	3.84e-06	0.000222	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CAV1—ovarian cancer	3.79e-06	0.000219	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.78e-06	0.000218	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.73e-06	0.000216	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMS—ovarian cancer	3.67e-06	0.000212	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.65e-06	0.000211	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.62e-06	0.000209	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.5e-06	0.000202	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CAV1—ovarian cancer	3.46e-06	0.0002	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CG—ovarian cancer	3.45e-06	0.0002	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CB—ovarian cancer	3.42e-06	0.000198	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.3e-06	0.000191	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.15e-06	0.000182	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.1e-06	0.000179	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CD—ovarian cancer	3.04e-06	0.000175	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—ovarian cancer	2.96e-06	0.000171	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CAV1—ovarian cancer	2.95e-06	0.000171	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.89e-06	0.000167	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.88e-06	0.000166	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMS—ovarian cancer	2.83e-06	0.000164	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.82e-06	0.000163	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.77e-06	0.00016	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.69e-06	0.000155	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.65e-06	0.000153	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.41e-06	0.000139	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.37e-06	0.000137	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—ovarian cancer	2.36e-06	0.000136	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—ovarian cancer	2.29e-06	0.000132	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CAV1—ovarian cancer	2.28e-06	0.000132	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.09e-06	0.000121	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—ovarian cancer	2.08e-06	0.00012	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.08e-06	0.00012	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.06e-06	0.000119	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.83e-06	0.000105	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—ovarian cancer	1.78e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—ovarian cancer	1.7e-06	9.85e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.61e-06	9.32e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.59e-06	9.2e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.47e-06	8.5e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—ovarian cancer	1.37e-06	7.95e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—ovarian cancer	1.32e-06	7.62e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.26e-06	7.26e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—ovarian cancer	1.2e-06	6.94e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—ovarian cancer	1.03e-06	5.93e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.7e-07	5.61e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—ovarian cancer	7.92e-07	4.58e-05	CbGpPWpGaD
